World Health Organization Favors Easier Access to OTC Birth Control

“Over-the-counter oral contraceptive pills (OCPs) should be made available without a prescription for individuals using OCPs.” — World Health Organization, WHO Consolidated Guideline on Self-Care Interventions for Health: Sexual and Reproductive Health and Rights (2019).

The World Health Organization (WHO) has taken a definitive position on contraceptive access, recommending that oral contraceptive pills be made available without a prescription as part of a broader strategy to expand access to reproductive healthcare.

The WHO classifies this as a strong recommendation, even though the supporting evidence is rated as very low certainty. In explaining this position, the guideline states: “Despite the very low-quality evidence, the GDG agreed that the benefits outweighed the harms.” (WHO Guideline, 2019, p. 57). The decision reflects how WHO develops policy guidance. Rather than relying solely on clinical trial strength, the organization weighs a broader set of considerations, including access, equity, feasibility, and the values and preferences of users. In this case, the WHO determined that reducing barriers to contraceptive access—particularly in settings where healthcare services are limited—offers significant public health benefits, including reducing unintended pregnancies and improving maternal health outcomes. At the same time, the guideline notes that screening for medical eligibility remains preferable at the point of initiation, acknowledging that some individuals may require clinical evaluation depending on underlying conditions.

The WHO’s position aligns with a broader international trend toward improving access to contraception. A 2022 study published in the Bulletin of the World Health Organization reviewed regulatory frameworks across 30 countries and found that formal systems for over-the-counter contraceptive access remain limited. Only four countries in the study formally included contraceptives on national over-the-counter medicine lists, even though access in practice is often less restricted. The study concludes that countries should develop regulatory pathways to reclassify contraceptives from prescription-only to over-the-counter status in order to improve access and health outcomes. The research also highlights a gap between policy and practice: in many countries, contraceptives are already widely accessed without prescriptions, meaning that stricter enforcement of prescription rules can have a direct impact on availability.

Both the WHO guideline and supporting research present a balanced view of over-the-counter access. Benefits include improved access and convenience, greater privacy and autonomy, and potential reductions in unintended pregnancies. However, the WHO also recognizes potential risks, including the need for self-assessment of medical eligibility, possible misuse without proper guidance, and increased out-of-pocket costs in some systems. Despite these trade-offs, the WHO’s conclusion remains that expanding access produces a net public health benefit, particularly in settings where barriers to care are significant.

The WHO’s recommendation comes as Belize implements a policy that moves in a different direction. In an April 15, 2026 press release, the Pharmacists Association of Belize (PAB) confirmed that oral contraceptives will continue to be dispensed only to women who previously obtained them with a valid prescription, while new users must now obtain one through a licensed provider. The policy, implemented in coordination with the Ministry of Health and Wellness, is part of a twelve-month phased enforcement of prescription requirements.

The move has drawn criticism from groups including the National Trade Union Congress of Belize (NTUCB), which argues that the requirement may create barriers for working women and place additional strain on an already burdened healthcare system.